Immunocore Holdings PLC is a commercial-stage biotechnology company... Show more
IMCR saw its Momentum Indicator move above the 0 level on April 01, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 60 similar instances where the indicator turned positive. In of the 60 cases, the stock moved higher in the following days. The odds of a move higher are at .
The Moving Average Convergence Divergence (MACD) for IMCR just turned positive on March 20, 2025. Looking at past instances where IMCR's MACD turned positive, the stock continued to rise in of 34 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMCR advanced for three days, in of 245 cases, the price rose further within the following month. The odds of a continued upward trend are .
IMCR moved below its 50-day moving average on March 28, 2025 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMCR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for IMCR entered a downward trend on March 14, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.085) is normal, around the industry mean (13.260). P/E Ratio (0.000) is within average values for comparable stocks, (64.931). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.878). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (4.744) is also within normal values, averaging (252.036).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. IMCR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
BRUGX | 15.47 | 0.11 | +0.72% |
MFS Blended Research Value Equity C | |||
ARTGX | 24.11 | 0.09 | +0.37% |
Artisan Global Value Investor | |||
FBPEX | 26.51 | N/A | N/A |
Cantor Fitzgerald Equity Div Plus Inst | |||
STDFX | 38.04 | N/A | N/A |
Allspring Large Cap Growth Admin | |||
GQGRX | 16.51 | N/A | N/A |
GQG Partners Emerging Markets Equity R6 |
A.I.dvisor indicates that over the last year, IMCR has been loosely correlated with CRBU. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if IMCR jumps, then CRBU could also see price increases.
Ticker / NAME | Correlation To IMCR | 1D Price Change % | ||
---|---|---|---|---|
IMCR | 100% | +2.79% | ||
CRBU - IMCR | 38% Loosely correlated | +2.37% | ||
IMNM - IMCR | 37% Loosely correlated | +7.19% | ||
SPRB - IMCR | 37% Loosely correlated | +9.21% | ||
KYMR - IMCR | 37% Loosely correlated | +4.46% | ||
IDYA - IMCR | 36% Loosely correlated | +10.70% | ||
More |